Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 5, 2017, Pages E689-E696

  Li, Quan ^a   Henry, Eric R ^a   Hofrichter, James ^a   Smith, Jeffrey F ^a   Cellmer, Troy ^a   Dunkelberger, Emily B ^a   Metaferia, Belhu B ^a   Jones Straehle, Stacy ^a   Boutom, Sarah ^a   Christoph, Garrott W ^a   Wakefield, Terri H ^a   Link, Mary E ^b   Staton, Dwayne ^a   Vass, Erica R ^a   Miller, Jeffery L ^a   Hsieh, Matthew M ^b   Tisdale, John F ^b   Eaton, William A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Drugs; Hemoglobin S; Screening assay; Sickle cell; Treatment

Indexed keywords

HYDROXYUREA; POLYMERIZED HEMOGLOBIN; 5-HYDROXYMETHYLFURFURAL; ANTISICKLING AGENT; FURFURAL; HEMOGLOBIN S; OXYGEN;

CONFERENCE PAPER; ERYTHROCYTE MEMBRANE; ERYTHROCYTE VOLUME; FOOD AND DRUG ADMINISTRATION; HEMOGLOBIN DETERMINATION; HUMAN; KINETICS; OXYGEN AFFINITY; PHOTOLYSIS; PRIORITY JOURNAL; SCREENING TEST; SICKLE CELL; SICKLE CELL ANEMIA; SICKLE CELL TRAIT; THERAPY EFFECT; THERMODYNAMICS; ANALOGS AND DERIVATIVES; CELL SIZE; DRUG EFFECTS; ERYTHROCYTE; METABOLISM; PHYSIOLOGY;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CELL SIZE; ERYTHROCYTES; FURALDEHYDE; HEMOGLOBIN, SICKLE; HUMANS; KINETICS; OXYGEN;

EID: 85011305922     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1619054114     Document Type: Article

References (54)

1. Singh PC, Ballas SK (2015) Emerging drugs for sickle cell anemia. Expert Opin Emerg Drugs 20(1):47-61.
2. Ataga KI, Stocker J (2015) The trials and hopes for drug development in sickle cell disease. Br J Haematol 170(6):768-780.
3. Kato GJ (2016) New insights into sickle cell disease: Mechanisms and investigational therapies. Curr Opin Hematol 23(3):224-232.
4. Pauling L, Itano HA, Singer SJ, Wells IC (1949) Sickle cell anemia a molecular disease. Science 110(2865):543-548.
5. Piel FB, et al. (2013) Global epidemiology of sickle haemoglobin in neonates: A contemporary geostatistical model-based map and population estimates. Lancet 381(9861): 142-151.
6. Hsieh MM, Fitzhugh CD, Tisdale JF (2011) Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood 118(5):1197-1207.
7. Sankaran VG, Weiss MJ (2015) Anemia: Progress in molecular mechanisms and therapies. Nat Med 21(3):221-230.
8. Steinberg MH, Chui DHK, Dover GJ, Sebastiani P, Alsultan A (2014) Fetal hemoglobin in sickle cell anemia: A glass half full? Blood 123(4):481-485.
9. Fitzhugh CD, et al. (2015) Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia. PLoS One 10(11):e0141706.
10. Mozzarelli A, Hofrichter J, Eaton WA (1987) Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Science 237(4814):500-506.
11. Noguchi CT, Torchia DA, Schechter AN (1983) Intracellular polymerization of sickle hemoglobin. Effects of cell heterogeneity. J Clin Invest 72(3):846-852.
12. Hebbel RP (1991) Beyond hemoglobin polymerization: The red blood cell membrane and sickle disease pathophysiology. Blood 77(2):214-237.
13. Sunshine HR, Hofrichter J, Eaton WA (1978) Requirement for therapeutic inhibition of sickle haemoglobin gelation. Nature 275(5677):238-240.
14. Eaton WA, Hofrichter J (1987) Hemoglobin S gelation and sickle cell disease. Blood 70(5):1245-1266.
15. Bunn HF (1997) Pathogenesis and treatment of sickle cell disease. N Engl J Med 337(11):762-769.
16. Ferrone FA (2015) The delay time in sickle cell disease after 40 years: A paradigm assessed. Am J Hematol 90(5):438-445.
17. Platt OS, et al. (1984) Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 74(2):652-656.
18. Charache S, et al.; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332(20):1317-1322.
19. Eaton WA, Hofrichter J (1995) The biophysics of sickle cell hydroxyurea therapy. Science 268(5214):1142-1143.
20. Bridges KR, et al. (1996) A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 88(12):4701-4710.
21. Lanzkron S, Haywood C, Jr, Segal JB, Dover GJ (2006) Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol 81(12):927-932.
22. Steinberg MH, et al.; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 85(6):403-408.
23. Bauer DE, Kamran SC, Orkin SH (2012) Reawakening fetal hemoglobin: Prospects for new therapies for the β-globin disorders. Blood 120(15):2945-2953.
24. Hofrichter J, Ross PD, Eaton WA (1976) Supersaturation in sickle cell hemoglobin solutions. Proc Natl Acad Sci USA 73(9):3035-3039.
25. Poillon WN, Kim BC (1990) 2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S. Blood 76(5):1028-1036.
26. Brugnara C, Bunn HF, Tosteson DC (1986) Regulation of erythrocyte cation and water content in sickle cell anemia. Science 232(4748):388-390.
27. Zarkowsky HS, Hochmuth RM (1975) Sickling times of individual erythrocytes at zero Po2. J Clin Invest 56(4):1023-1034.
28. Sunshine HR, Hofrichter J, Eaton WA (1979) Gelation of sickle cell hemoglobin in mixtures with normal adult and fetal hemoglobins. J Mol Biol 133(4):435-467.
29. Eaton WA, Hofrichter J (1990) Sickle cell hemoglobin polymerization. Adv Protein Chem 40:63-279.
30. Rotter M, Yosmanovich D, Briehl RW, Kwong S, Ferrone FA (2011) Nucleation of sickle hemoglobin mixed with hemoglobin A: Experimental and theoretical studies of hybrid-forming mixtures. Biophys J 101(11):2790-2797.
31. Christoph GW, Hofrichter J, Eaton WA (2005) Understanding the shape of sickled red cells. Biophys J 88(2):1371-1376.
32. Coletta M, Hofrichter J, Ferrone FA, Eaton WA (1982) Kinetics of sickle haemoglobin polymerization in single red cells. Nature 300(5888):194-197.
33. Cellmer T, Ferrone FA, Eaton WA (2016) Universality of supersaturation in proteinfiber formation. Nat Struct Mol Biol 23(5):459-461.
34. Lew VL, Raftos JE, Sorette M, Bookchin RM, Mohandas N (1995) Generation of normal human red cell volume, hemoglobin content, and membrane area distributions by "birth" or regulation? Blood 86(1):334-341.
35. Brittenham GM, Schechter AN, Noguchi CT (1985) Hemoglobin S polymerization: Primary determinant of the hemolytic and clinical severity of the sickling syndromes. Blood 65(1):183-189.
36. Bunn HF, et al. (1982) Molecular and cellular pathogenesis of hemoglobin SC disease. Proc Natl Acad Sci USA 79(23):7527-7531.
37. Nagel RL, Fabry ME, Steinberg MH (2003) The paradox of hemoglobin SC disease. Blood Rev 17(3):167-178.
38. Clark MR, Mohandas N, Shohet SB (1982) Hydration of sickle cells using the sodium ionophore Monensin. A model for therapy. J Clin Invest 70(5):1074-1080.
39. Safo MK, Kato GJ (2014) Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. Hematol Oncol Clin North Am 28(2):217-231.
40. Oksenberg D, et al. (2016) GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Brit J Hematol 175(1):141-53.
41. Patel M, et al. (2016) Pharmacokinetics (PK) and pharmacodynamics (PD) of GBT440, a novel hemoglobin S (HbS) polymerization inhibitor for the treatment of sickle cell disease (SCD) in healthy volunteers and SCD patients. Haematologica 101:124-125.
42. Bradner JE, et al. (2010) Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci USA 107(28):12617-12622.
43. Li H, et al. (2013) Development of phenotypic screening assays for γ-globin induction using primary human bone marrow day 7 erythroid progenitor cells. J Biomol Screen 18(10):1212-1222.
44. Peterson KR, et al. (2014) A cell-based high-throughput screen for novel chemical inducers of fetal hemoglobin for treatment of hemoglobinopathies. PLoS One 9(9): e107006.
45. Chou YC, et al. (2015) Pharmacological induction of human fetal globin gene in hydroxyurea-resistant primary adult erythroid cells. Mol Cell Biol 35(14):2541-2553.
46. Boosalis MS, et al. (2015) Novel inducers of fetal globin identified through high throughput screening (HTS) are active in vivo in anemic baboons and transgenic mice. PLoS One 10(12):e0144660.
47. Nakagawa A, et al. (2014) Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling. ACS Chem Biol 9(10): 2318-2325.
48. Hofrichter J, Ross PD, Eaton WA (1974) Kinetics and mechanism of deoxyhemoglobin S gelation: A new approach to understanding sickle cell disease. Proc Natl Acad Sci USA 71(12):4864-4868.
49. Eaton WA, Hofrichter J, Ross PD (1976) Editorial: Delay time of gelation: A possible determinant of clinical severity in sickle cell disease. Blood 47(4):621-627.
50. Sunshine HR, Hofrichter J, Ferrone FA, Eaton WA (1982) Oxygen binding by sickle cell hemoglobin polymers. J Mol Biol 158(2):251-273.
51. Kato GJ, et al. (2013) Phase 1 clinical trial of the candidate anti-sickling agent Aes-103 in adults with sickle cell anemia. Blood 122:1009.
52. Abdulmalik O, et al. (2005) 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol 128(4):552-561.
53. Lehrer-Graiwer J, et al. (2015) GBT440, a potent anti-sickling hemoglobin modifier reduces hemolysis, improves anemia and nearly eliminates sickle cells in peripheral blood of patients with sickle cell disease. Blood 126(23):542.
54. Swift R, et al. (2016) SCD-101: A new anti-sickling drug reduces pain and fatigue and improves red blood cell shape in peripheral blood of patients with sickle cell disease. Blood 128(22):121.